TY - JOUR
T1 - The role of postoperative radiation therapy for endometrial cancer
T2 - Executive summary of an American society for radiation oncology evidence-based guideline
AU - Klopp, Ann
AU - Smith, Benjamin D.
AU - Alektiar, Kaled
AU - Cabrera, Alvin
AU - Damato, Antonio L.
AU - Erickson, Beth
AU - Fleming, Gini
AU - Gaffney, David
AU - Greven, Kathryn
AU - Lu, Karen
AU - Miller, David
AU - Moore, David
AU - Petereit, Daniel
AU - Schefter, Tracey
AU - Small, William
AU - Yashar, Catheryn
AU - Viswanathan, Akila N.
N1 - Funding Information:
Conflicts of interest: Before initiation of this guideline all members of the guideline panel were required to complete disclosure statements. These statements are maintained at the American Society for Radiation Oncology (ASTRO) headquarters in Fairfax, VA and pertinent disclosures are published with the report. The ASTRO Conflict of Interest Disclosure Statement seeks to provide a broad disclosure of outside interests. Where a potential conflict is detected, remedial measures to address any potential conflict are taken and will be noted in the disclosure statement. Ann Klopp, MD, PhD, has research funding from the Ovarian Cancer Research Foundation and the MD Anderson Cancer Center Endometrial and Ovarian Spore. Benjamin Smith, MD, has received research grants from Conquer Cancer Foundation and Cancer Prevention and Research Institute of Texas. He also serves as a consultant for Conquer Cancer Foundation. Akila Viswanathan, MD is the principal investigator for NIH R21 167800. She is President of the American Brachytherapy Society, and serves as a gyn specialist for Chartrounds.com and the Brachytherapy Consortium for Nucletron/Elekta. Catheryn Yashar, MD, serves as a consultant to and owns stock in Cianna Medical. The guideline panel chairs as well as the chair of the guideline subcommittee reviewed these disclosures and determined that they do not present a conflict with respect to these panel members' work on this guideline.
PY - 2014/5
Y1 - 2014/5
N2 - Purpose: To present evidence-based guidelines for adjuvant radiation in the treatment of endometrial cancer. Methods and materials: Key clinical questions to be addressed in this evidence-based guideline on endometrial cancer were identified. A comprehensive literature review was performed to identify studies that included no adjuvant therapy, or pelvic radiation or vaginal brachytherapy with or without systemic chemotherapy. Outcomes included local control, survival rates, and overall assessment of quality of life. Results: Patients with grade 1 or 2 cancers with either no invasion or < 50% myometrial invasion (MI), especially when no other high risk features are present, can be safely observed after hysterectomy. Vaginal cuff brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence for patients with grade 1 or 2 cancers with ≥. 50% MI or grade 3 tumors with < 50% MI. Patients with grade 3 cancer with ≥. 50% MI or cervical stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence. There is limited evidence for a benefit to vaginal cuff brachytherapy following pelvic radiation. Multimodality treatment is recommended for patients with positive nodes or involved uterine serosa, ovaries or fallopian tubes, vagina, bladder, or rectum. Conclusions: External beam and vaginal brachytherapy remain integral aspects of adjuvant therapy for endometrial cancer.
AB - Purpose: To present evidence-based guidelines for adjuvant radiation in the treatment of endometrial cancer. Methods and materials: Key clinical questions to be addressed in this evidence-based guideline on endometrial cancer were identified. A comprehensive literature review was performed to identify studies that included no adjuvant therapy, or pelvic radiation or vaginal brachytherapy with or without systemic chemotherapy. Outcomes included local control, survival rates, and overall assessment of quality of life. Results: Patients with grade 1 or 2 cancers with either no invasion or < 50% myometrial invasion (MI), especially when no other high risk features are present, can be safely observed after hysterectomy. Vaginal cuff brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence for patients with grade 1 or 2 cancers with ≥. 50% MI or grade 3 tumors with < 50% MI. Patients with grade 3 cancer with ≥. 50% MI or cervical stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence. There is limited evidence for a benefit to vaginal cuff brachytherapy following pelvic radiation. Multimodality treatment is recommended for patients with positive nodes or involved uterine serosa, ovaries or fallopian tubes, vagina, bladder, or rectum. Conclusions: External beam and vaginal brachytherapy remain integral aspects of adjuvant therapy for endometrial cancer.
UR - http://www.scopus.com/inward/record.url?scp=84898812959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898812959&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2014.01.003
DO - 10.1016/j.prro.2014.01.003
M3 - Article
C2 - 24766678
AN - SCOPUS:84898812959
SN - 1879-8500
VL - 4
SP - 137
EP - 144
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 3
ER -